DNLI Denali Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1714899 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY37.0%
TTM EPS YoY41.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-33.9%
ROA-27.2%
ROIC (approx.)-50.8%
Asset turnover—
Leverage & solvency
Liabilities / assets26.2%
Debt / equity0.00x
Current ratio6.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.41x
Accruals ratio11.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $330.53M | $108.46M | $48.66M |
| R&D expense | $418.78M | $396.44M | $423.88M | $358.73M | $265.35M |
| SG&A expense | $136.56M | $105.44M | $103.35M | $90.47M | $79.06M |
| Operating income | -$555.34M | -$487.34M | -$196.70M | -$340.74M | -$295.75M |
| Income tax | $102,000 | $68,000 | $30,000 | $21,000 | -$575,000 |
| Net income | -$512.54M | -$422.77M | -$145.22M | -$325.99M | -$290.58M |
| EBITDA | -$544.16M | -$479.55M | -$179.97M | -$330.36M | -$287.16M |
| EPS (basic) | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 |
| EPS (diluted) | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 |
| Weighted avg. shares (diluted) | 172.65M | 164.47M | 137.37M | 125.53M | 121.52M |
| Balance sheet | |||||
| Cash & equivalents | $205.33M | $176.53M | $128.68M | $219.54M | $294.98M |
| Short-term investments | $662.55M | $657.37M | $907.40M | $1.12B | $571.93M |
| Receivables | $0 | — | — | — | — |
| Inventory | $0 | — | — | — | — |
| Current assets | $900.66M | $864.44M | $1.06B | $1.37B | $897.23M |
| PP&E, net | $52.40M | $55.24M | $45.59M | $44.09M | $38.87M |
| Intangibles | $0 | — | — | — | — |
| Total assets | $1.14B | $1.37B | $1.15B | $1.46B | $1.40B |
| Current liabilities | $98.35M | $102.21M | $77.98M | $363.92M | $378.25M |
| Total liabilities | $131.09M | $144.50M | $122.96M | $417.81M | $441.87M |
| Shareholders' equity | $1.01B | $1.23B | $1.03B | $1.04B | $962.29M |
| Shares outstanding | 156.18M | 144.22M | 138.39M | 135.97M | 122.28M |
| Cash flow statement | |||||
| Operating cash flow | -$412.60M | -$347.69M | -$357.99M | -$244.72M | -$211.39M |
| Capital expenditure | $9.50M | $15.91M | $12.94M | $17.83M | $8.50M |
| Free cash flow | -$422.10M | -$363.61M | -$370.93M | -$262.55M | -$219.89M |
| Investing cash flow | $255.28M | -$88.76M | $249.31M | -$141.39M | -$21.63M |
| Financing cash flow | $189.22M | $484.30M | $17.82M | $310.67M | $19.35M |
| Depreciation & amortization | $11.18M | $7.79M | $16.73M | $10.38M | $8.59M |
| Stock-based compensation | $99.63M | $102.88M | $108.10M | $99.85M | $85.25M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.